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Abstract

It had been shown previous to this research that
supplementation with choline and pantothenic acid results in
reduced plasma concentrations and urinary excretion of
carnitine in adult humans. This research demonstrated
similar effects in younger human subjects and developed an
animal model for future study of the interaction of choline
and pantothenic acid with carnitine.
Rats were first used as an animal model but neither
choline, pantothenic acid, nor both combined had any effect
on urinary or plasma carnitine concentration. It was
concluded that rats were not an acceptable model, possibly
because of the high choline oxidase activity present in rat
liver.
Guinea pigs were then tested as an animal model and
were found to have reduced urinary excretion of carnitine in
response to choline supplementation, but not pantothenic
acid supplementation. Plasma concentrations of carnitine in
guinea pigs were unaffected by either choline, pantothenic
acid or both combined. It was concluded that choline was the
supplement responsible for reducing plasma and urinary
excretion of carnitine in guinea pigs, and that guinea pigs
provide an acceptable model for future study of interactions
of choline and pantothenic acid in humans.
iii
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Chapter 1
Introduction
Carnitine and choline are both recognized as essential
for metabolic processes; neither, however, are considered
essential nutrients as they are synthesized in the human
body. The possibility that under certain conditions,
suboptimal quantities may be synthesized by some individuals
and that supplemental levels of intake may confer benefits
has resulted in the use of both as dietary supplements
(1,2). Much of the interest in supplementary choline has
focused on its lipotropic action and on its effects on brain
function as a result of increased acetylcholine synthesis
(3-5). Choline is usually one of the ingredients in the
"smart drinks" that are currently popular as an alternative
to alcoholic beverages. Choline has long been known to be
essential for membrane phospholipids, as a source of labile
methyl groups, and for the synthesis of acetylcholine.
Recently, however, several choline derivatives have been
recognized as essential for intracellular second messenger
systems. Phosphatidylcholine products resulting from the
action of phospholipase C, D, and A2 , and products of
sphingomyelin degradation by sphingomyelinase are important
for intracellular signaling (for a brief review of choline's
involvement in intracellular signalling see reference 6).
1

Platelet activating factor also contains choline and is
involved in such diverse functions as blood clotting,
inflammation, pulmonary regulation, and allergic reactions
(6} •

Carnitine is structurally very similar to choline, but
quite different in function. Carnitine is best known for its
role in transporting long-chain fatty acids into the
mitochondria of cells, but also is useful in shuttling fatty
acids between different tissues and in removing short chain
fatty acids from the mitochondria thereby maintaining a pool
of free coenzyme A inside the mitochondria (1,7-9).
Our laboratory first became interested in choline when
doing a survey of carnitine excretion and plasma
concentrations in college students. one subject had
significantly lower plasma carnitine concentration and very
low urinary excretion of carnitine. The subject was
questioned about dietary habits and it was discovered that
she was taking supplementary choline and pantothenic acid
(10}. A study was undertaken giving choline and pantothenic
acid supplements to subjects and comparing plasma carnitine
concentrations and urinary excretion of carnitine to
controls. The subjects given choline and pantothenic acid,
as expected, had decreased carnitine concentrations in the
plasma and excreted less carnitine in the urine, thus
confirming the single observation. We had no basis to judge
the mechanism of the alteration in carnitine concentrations
2

by choline or even to judge whether the effect was harmful,
beneficial, or of no consequence. We also were uncertain if
the observed effect was a result of the choline and/or the
pantothenic acid.
The purposes of the studies reported here were to develop
an animal model to study the reduced plasma concentration
and urinary excretion of carnitine by choline and
pantothenic acid effect in humans, to determine if the
effect was mediated by choline or pantothenic acid, and to
determine the mechanism involved. Studies in our laboratory
and others using rats as an animal model found no effect of
choline on either urinary excretion or plasma concentrations
of carnitine. We concluded that this was probably due to the
high activity of choline oxidase in rat liver, and that
using an animal with similar choline oxidase activity to
humans should be used. The guinea pig was chosen because the
liver choline oxidase activity is most similar to that of
humans of any common laboratory animal (11).

3

Chapter 2
Literature Review
Choline
Choline is a quaternary trimethylated amine as is
carnitine, another nutrient of primary importance in this
research. Choline is synthesized de novo in humans but also
is widely available in the diet. Choline deficiency has been
induced in animals resulting in liver damage, renal
hemorrhage, and inability of the liver to export
triglyceride with hepatic fat accumulation resulting (12).
There has never been a case of choline deficiency syndrome
observed in humans, probably because of it's ubiquitous
nature in the human diet.
Choline in the diet:

Daily dietary intake of choline in humans is estimated
to be between 600 and 900 mg per day (12). Choline is
available in the diet as both choline chloride and
phosphatidylcholine (lecithin). The best sources of choline
include meat, eggs, oatmeal, soybeans, wheat germ, peanuts,
and other nuts and grains (13). The most abundant form of
choline in the diet is lecithin, but many foods contain
significant amounts of choline chloride, especially liver
and soybeans. Choline is also obtained in the diet from
sources other than naturally occurring foods. Lecithin is a
common food additive because of its ability to emulsify
4

fats, is an ingredient in frying pan sprays, and is
available as a vitamin supplement as lecithin or choline
chloride. Lecithin is usually the preferred source of
supplementary choline because intestinal bacteria can
degrade free choline to trimethylamine which produces an
unpleasant body odor and breath (13).
Absorption of choline:
Free choline is absorbed in the upper small intestine,
primarily in the jejunum in rats and hamsters (14). The
absorption appears to utilize an unidentified carrier at low
concentrations that is not sodium dependent but that is
saturable at concentrations above 4 mM. At concentrations
above 4 mM choline is absorbed by passive diffusion and
proportional to intraluminal choline concentrations (15).
Once absorbed choline enters the portal circulation as do
other water soluble molecules (13).
The majority of choline in the diet is in the form of
lecithin which is absorbed more like a fat. Pancreatic juice
contains phospholipase A 2 which cleaves the middle fatty
acid from the phosphatidylcholine molecule forming one
lysolecithin and one free fatty acid from each molecule.
Approximately half of the absorbed phosphatidylcholine is
absorbed in the form of lysolecithin which is reacylated in
the intestinal mucosa and exported to the lymphatic system
as chylomicrons or very low density lipoproteins. The other
half of the phosphatidylcholine is completely hydrolyzed to
5

free fatty acids and free choline and the choline absorbed
as described above (16,17,18).
Non Dietary Sources of Choline:
Lecithin is formed in mammals by three different
pathways; the base exchange pathway, CDP-choline pathway,
and the methyltransferase pathway (13). The base exchange
pathway simply exchanges choline for another base on a
phospholipid, the CDP-choline pathway uses diacylglycerol
and free choline to form phosphatidylcholine. The
methyltransferase pathway is the only pathway that actually
synthesizes new choline. In the methyltransferase pathway
phosphatidylethanolamine is sequentially methylated by
phosphatidylethanolamine-N-methyltransferase (PEMT) using

s

adenosyl methionine (SAM) as the methyl source (19,20). PEMT
is most concentrated in the liver but is also found in
kidney, testes, heart, lung, adrenal gland, erythrocytes,
spleen, and brain (21,22,23).

In the rat about 15% of the

choline requirement is supplied by the methylation pathway
with the remainder obtained from the diet (13,24,25). The
percentage of choline that must be obtained from the diet in
humans is not something that is well understood currently,
but human dietary requirements for choline will be discussed
later.
PEMT is actually two enzymes that catalyze the
methylation of phosphatidylethanolamine. The first
methylation is the rate limiting step and is facilitated by
6

an enzyme located on the cytoplasmic side of the plasma
membrane in erythrocytes, and is followed by two subsequent
methylations by an enzyme located on the exterior side of
the plasma membrane (22,26). The first methyltransferase,
which methylates phosphatidylethanolamine to
phosphatidylmethylethanolamine, is Mg2 + dependent, has an
optimum pH of 6. 5 and a high affinity for SAM (Km of 1. 4
µM). The second methyltransferase is not Mg2+ dependent, has
an optimum pH of 10 and has a much lower affinity for SAM
(Km of 100 µM). Choline deficiency and ethanol exposure
increase the activity of the methylation pathway of lecithin
synthesis (27, 28,29).
Choline in single carbon metabolism:

Choline is frequently referred to as an important
source of labile methyl groups (2). s-adenosyl methionine is
the active agent in many synthesis reactions requiring
addition of a methyl group (30). When SAM donates its methyl
group it is hydrolyzed to form homocysteine and adenosine.
The methionine may be regenerated by the transfer of a
methyl group to homocysteine. The methyl group may be
obtained either from N5-tetrahydrofolate in a reaction
catalyzed by homocysteine methyltransferase, or from betaine
in a reaction catalyzed by betaine-homocysteine
methyltransferase (31). Both reactions appear to be of about
equal importance in the rat (32,33).
Methotrexate is a commonly used cancer therapeutic
7

agent which is a competitive inhibitor of dihydrofolate
reductase thereby blocking the regeneration of methionine by
the folate pathway. When rats are treated with methotrexate
the liver is rapidly depleted of SAM, choline,
phosphocholine, and betaine; the liver becomes fatty and
liver function is impaired. Supplementation with choline can
prevent the above symptoms in rats, at least for up to three
months (34,35). Clearly choline is able to largely replace
folate in methyl metabolism in rats.
Whether choline is a significant source of labile
methyl groups in humans is uncertain (31). The following
pathway is the only way that methyl groups from choline may
be utilized (36).
Choline
Choline Oxidase
Betaine Aldehyde
Betaine Aldehyde
Dehydrogenase
Betaine
Dimethylglycine + methyl
group
Betaine-homocysteine
Methyltransferase
Homocysteine��������-> Methionine
Choline oxidase, however, is present in very low
concentrations in the human liver compared to most animals.
8

Table 1 shows choline oxidase activity in several animals
and man. Studies investigating choline as a methyl donor
have used rats as the model and may not apply to humans
since rats have 60 times the choline oxidase activity of
humans. It is quite possible that choline is not able to
significantly contribute to the labile methyl pool in humans
even though humans do have active liver betaine-homocysteine
methyltransferase (37). To suggest that choline may not be
an important methyl donor in humans does not suggest that
choline does not have important functions in humans, because
there are other critical functions for choline in humans
which are discussed in the next sections.
Choiine and acetyichoiine:

The central nervous system communicates between nerve cells
and other cells using chemical messengers called
neurotransmitters; one of the most important of these is

Table 1
Liver Choline Oxidase in Selected Species
Species

Choline Oxidase Activity

Rat
Chicken
Mouse
Hamster
Monkey
Guinea Pig
Human

2408
1311
895
361
144
136
40

± 121
± 86
± 72
± 63
± 21
+ 43
± 7

Taken from Sidransky and Farber, reference 11. Activity
units are in microliters of 0 2 uptake/hr/g wet liver ± SEM.
9

acetylcholine. Acetylcholine is one of the neurotransmitters
between neurons in the central nervous system; the
neurotransmitter between neurons and somatic motor neurons
at the neuromuscular junction, and between parasympathetic
nerve endings (38). Acetylcholine is synthesized by the
transfer of an acetyl group from acetyl CoA to choline in a
reaction catalyzed by choline acetyltransferase (39). Enzyme
kinetics studies of choline acetyltransferase in brain
tissue suggest that the enzyme is unlikely ever to be
saturated and that choline and/or acetyl CoA availability
determine the rate of acetylcholine synthesis (34,40).
Cohen and Wurtman (41) found that brain (particularly
the caudate nucleus) acetylcholine varied on a day to day
basis with dietary intake, though remaining within the
normal range for rats. Others, however, have not found
steady state acetylcholine concentrations to be affected by
dietary variations but only found increases in acetylcholine
under induced conditions of increased cholinergic neuronal
activity (42). Cognitive benefit from using choline
supplements (as in "smart drinks") has yet to be
demonstrated, but benefits have been demonstrated in some
diseases involving cholinergic neurons. Choline and lecithin
have been used most successfully in treatment of tardive
dyskinesia, but some benefit have also been reported in the
treatment of Huntington's chorea, Alzheimer's disease, and
ataxia (36).
10

Choline in membrane phospholipid:

Choline in the forms of phosphatidylcholine and
sphingomyelin is a major structural component of mammalian
cell membranes. Phosphatidylcholine makes up approximately
50% of the phospholipid content of cell membranes and
sphingomyelin 5-20%, depending on the cell type (43). It has
recently become clear that choline phospholipids in
membranes are much more than just structural components, but
are essential for intracellular signal transduction
(33,43,44).

One of the best understood mechanisms of intracellular
signalling occurs when a hormone binds to a receptor protein
activating a G protein which in turn activates phospholipase

c. Phospholipase C hydrolyses the phosphate from

phosphatidylinositol generating inositol 1,4,5-trisphosphate
(IP3) and diacylglycerol (45). The hydrolysis of
phosphatidylinositol results in the activation of protein
kinase c which requires binding of diacylglycerol and Ca 2+
for activation. The diacylglycerol is supplied directly from
the hydrolysis, and Ca2+ indirectly; IP3 causes the release
of stored intracellular calcium. It was reported in 1981
that the diacylglycerol released as a result of cholinergic
stimulation of rat pancreas did not resemble the fatty acid
composition of phosphatidylinositol (46,47). In 1985 the
first evidence that hormones can promote phosphatidylcholine
hydrolysis was reported (48). Hepatocytes stimulated with a
11

calcium mobilizing agonist were shown by high performance
liquid chromatography to have two primary types of
diacylglycerol. One type had higher concentrations of
palmitic, oleic, and linoleic acids than normally found in
phosphatidylinositol, which is typically rich in arachidonic
and stearic acids. It was therefore suggested that
phosphatidylcholine was the source of the diacylglycerols
(46,47,49).

Apparently, a frequently occurring scenario is that
diacylglycerol is initially released primarily from
phosphatidylinositol as a result of the action of
phospholipase c. The initial release is followed by a longer
lived and greater release from phosphatidylcholine as a
result of a phosphatidylcholine specific phospholipase C
and/or D. Phospholipase D hydrolysis produces a phosphatidic
acid from which the phosphate is cleaved by phosphatidic
acid phosphohydrolase thus releasing DAG (44,46).
studies of phosphatidylcholine hydrolysis show that
calcium depletion in hepatocytes blocked diacylglycerol
formation whereas addition of the calcium ionophore A23187
potentiated the hydrolysis (46,50). The requirement for Ca2+
in the hydrolysis of phosphatidylcholine suggested a
possible role for protein kinase c since binding of ca2+ to
this enzyme is required for it's activation. This was
demonstrated to be the case in rat brain where it was shown
that purified protein kinase C can activate a
12

phosphatidylcholine hydrolyzing phospholipase D (51).

A

possible role for the hydrolysis of phosphatidylcholine
subsequent to protein kinase c activation is to maintain the
activation for a longer time. When protein kinase C is
activated by Ca2+ and diacylglycerol, the diacylglycerol
binds for only a short time, but the calcium dissociates
rather slowly. The addition of further diacylglycerol may be
useful in maintaining the activation of protein kinase C
(43), which may be made possible by activation of the
phospholipase D & C by protein kinase C. Far more
diacylglycerol can be released from phosphatidylcholine than
from

phosphatidylinositol hydrolysis since cellular

phosphatidylcholine is several hundred times the
concentration of phosphatidylinositol (52).
There are also instances in which phosphatidylcholine
breakdown occurs without the prior breakdown of
phosphatidylinositol; examples include the activation of T
lymphocytes by interleukin 1 and the simulation of
fibroblasts by epidermal growth factor, both of which can
result in sustained elevation of intracellular
diacylglycerol for hours (46,53,54). It has been shown that
diacylglycerol can activate some protein kinase C isotypes
alone, which is interesting because during choline
deficiency in rats hepatocytes accumulate triglyceride and
diacylglycerol. The concentration of diacylglycerol can
reach levels that exceed that in normal stimulation,
13

resulting in protein kinase C activation (43,55). It has
been suggested that sustained activation of protein kinase C
may explain the spontaneous development of hepatic
carcinomas seen in choline deficient rats (55).
The study of phosphatidylcholine metabolites in
intracellular signalling is still very recent and the
mechanisms have not yet been clearly elucidated as with
phosphatidylinositol. The release of arachidonic acid by the
action of phospholipase A2 resulting in eicosanoid formation
is also an important mediator of metabolic events (56). This
is not limited to choline phospholipids, however, and will
not be covered here.
Another choline containing membrane phospholipid
involved in intracellular signaling is sphingomyelin, which
can be hydrolyzed to form ceramide and choline phosphate
(43). The hydrolysis of sphingomyelin can be activated by
several known factors including 1-a,25-dihydroxyvitamin D,
tumor necrosis factor, and y-interferon (57). Ceramide is a
potent inhibitor of cell growth and sphingosine an inhibitor
of protein kinase C (58,59). Choline itself has not yet been
reported as a signal transduction molecule and its function,
if any, when choline containing phospholipids are
hydrolyzed, is unknown.
Choline: an essential nutrient:

Choline has been shown to be an essential nutrient in
many animal species including rat, hamster, guinea pig, pig,
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dog, monkey, trout, and chicken (33). Choline deficiency
results in spontaneous liver cancer in rats without exposure
to carcinogens and is the only nutrient known whose
deficiency is known to result in malignancies (43,60).
Choline deficiency, in species for which it has been shown
to be an essential nutrient, can result in impaired hepatic,
renal, pancreatic function, memory loss, and decreased
growth (33). It has been difficult to demonstrate that
choline is an essential nutrient for humans, however, it has
been shown that human cells grown in culture have an
absolute requirement for choline (2,61). Malnourished humans
have decreased serum choline concentrations and parenterally
fed persons without choline supplementation develop abnormal
liver function, indicating that there may be a requirement
for choline in the diet (62,63,64).
Zeisel et al. conducted a human study in which the
study group was fed a choline free diet and a control group
was fed an identical diet with added choline (2). They found
decreased choline and phosphatidylcholine in plasma of the
choline deficient group as compared to control as expected,
but also the serum alanine aminotransferase activity
increased consistently over the three weeks of the diet and
the study was then terminated to avoid further risk to the
subjects.
Impairment of liver function seems to be consistent
among all species, including humans, during choline
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deficiency. It has been difficult to find cases of choline
deficiency disease in human populations because choline is
very plentiful in foods, and it would be difficult to
construct a diet of natural foods that is deficient in
choline This does not mean however, that choline is not
essential - just easily obtained. studies with artificial
diets indicate that choline is essential in human diets.

Carnitine
Carnitine, L-B-hydroxy-y-N-trimethylaminobutyric acid,
like choline is a quaternary, trimethylated amine.
Carnitine, also like choline is synthesized de novo in
humans, and is available in the diet - though not as
plentifully as choline (65). Carnitine was originally called
vitamin BT but this terms is no longer used since carnitine
is not considered essential in the diet of higher organisms.
Diseases of carnitine deficiency have been identified in
humans (65) and will be discussed later. These diseases are
usually very rare genetic disorders, and do not reflect a
need for carnitine in normal human nutrition (65).
Carnitine in the diet:

Dietary carnitine is derived primarily from animal food
sources, and the average nonvegetarian diet is estimated to
supply 100-300 mg of carnitine per day (65). Vegetables,
fruits, and grains are very poor sources of carnitine.
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Ground beef has about 580 µmol of carnitine per 100 grams
whereas asparagus (one of the richest vegetable sources) has
about 1. 2 µmol per 100 grams (65,66).
Dietary intake of carnitine has been shown to have a
significant influence on carnitine status in humans.
Children receiving total parenteral nutrition for 7. 2 years

± 2. 6 years from birth had total plasma carnitine

concentrations approximately half that of other children of
similar age serving as controls (66). When adults and
children eat either strict vegetarian diets, lacto
ovovegetarian diets, or mixed diets (including meat) for
long periods of time both plasma carnitine and urinary
excretion of carnitine have been shown to be affected (67).
Plasma carnitine differences between groups were small but
significant. Differences in urinary excretion of carnitine
were much greater, adult men on mixed diets,
lactoovovegetarian diets, or strict vegetarian diets
excreted 5. 79 ± 3. 08, 2. 1 ± 0. 76, and 1. 36 ± 0. 49 µmol
carnitine per kg body weight per day, respectively. Similar
trends were seen for male children as well as female adults
and children. The urinary excretion of carnitine decreased
proportionately with predicted carnitine intake. The
subjects eating diets highest in carnitine had the highest
excretion rate and those with diets lowest in carnitine
(strict vegetarian) had the lowest excretion rate.
How the differences in plasma carnitine and urinary
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carnitine excretion affect tissue concentrations is not
certain It has been shown in rats that dietary differences
do substantially affect tissue concentrations, but were
roughly proportional to plasma concentrations which had a
much greater variation than seen in the above mentioned
human study (68).
To what extent humans rely on dietary carnitine is
unknown. Cederblad and Lindsted report that synthesis
contributes four times more carnitine than does diet in
laboratory rats {69). In humans, however, dietary intake may
be more important since diet typically contributes 100-300
mg per day. The functional consequences of variations in
dietary intake of carnitine in humans are not known at this
time, but it is clear that dietary intake can affect plasma
and tissue concentrations in rats.
Intestinal absorption and tissue uptake of carnitine:

It has been difficult for researchers to determine the
percentage of carnitine absorbed from the diet. It was
assumed for many years that carnitine was nearly 100%
absorbed because when labeled carnitine was given orally,
little radioactivity showed up in the feces. Kinetic
analysis in animals and humans, however, indicated that
there was a higher rate of excretiori than was reported
(70, 71,72). In the kinetic studies, the carnitine was given
intravenously and no metabolites of carnitine were found in
urine or feces. When radioactively labeled carnitine was fed
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orally to rats, however, as much as 34% of the radioactivity
was found in excreted metabolites of carnitine in urine and
to a small extent in feces (73). When humans are fed
radioactive carnitine 95% of the radioactivity is absorbed
from the intestinal tract, but several metabolites show up
in the urine, primarily trimethylamine N-oxide (70).
Apparently intestinal bacteria degrade carnitine to other
metabolites which are in turn absorbed and then excreted in
the urine. Recent studies indicate that carnitine is 54-87%
absorbed without degradation depending on the dosage (70).
Carnitine is absorbed both actively and passively
across the intestinal mucosa (65). Active carnitine
absorption is a sodium linked process similar to the
absorption of phosphate (74,75,76). Carnitine enters the
blood stream via the portal circulation and circulates as
free or acyl carnitines (65). Most tissue cells transport
carnitine against a concentration gradient resulting in a
10-100 fold greater intracellular concentration (65),
suggesting an active transport mechanism there also.
Caxnicine biosynthesis:

Carnitine is synthesized from two essential amino acids
in all mammals including humans (9). The nitrogen and carbon
backbone of carnitine are derived from lysine and the methyl
groups attached to the nitrogen from SAM. Table 2 shows the
steps in carnitine biosynthesis, and the nutrients required
as cofactors (65,77).
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Table 2
Steps in Biosynthesis of Carnitine
And Nutrient Requirements
Step

Reactant

Product

Required Nutrient
Methionine, Lysine

1. Lysine

N-trimethyl-lysine

2. N-trimethyl-

N-trimethyl-3hydroxylysine

Vitamin c, Iron

3. N-trimethyl3-hydroxylysine

4-N-trimethylamino
butryaldehyde

Vitamin B6

lysine

4. 4-N-trimethylamino 4-N-trimethylamino
butyraldehyde
butyric acid

Niacin

5. 4-N-trimethylamino L-carnitine

Vitamin c, Iron

butyric acid

In step 1 lysine is methylated as a post-translational
modification in proteins including actin, myosin, and
histones; and N-trimethyl-lysine is released as a result of
enzymatic degradation of those proteins (65,78,79). Steps 25 in table 5 occur in both the liver and kidney in higher
mammals (78,80).

It is not clear how much effect diets

deficient in the nutrients involved in carnitine
biosynthesis have on carnitine status. Wheat gluten diets
(deficient in lysine) have little effect on carnitine
concentrations in adult rats (81), however, weanling rats
fed a lysine deficient diet will become carnitine deficient
(82, 83).
Vitamin c deficiency has also been proposed to affect
carnitine status since it is required for its biosynthesis.
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Vitamin C deficiency has been shown to result in decreased
activity of hepatic y-butyrobetaine hydroxylase and hepatic
and renal €-N-trimethyllysine hydroxylase (87). It was not
determined, however, if the effect on enzyme activity
altered carnitine status.
Iron has an obligatory role in carnitine synthesis and
a deficiency could impair the process. Nutritional iron
deficiency in pregnant rats results in hypertriglyceridemia
in both mother and pups, which can be reversed with iron
supplementation (84). Pregnant rats continued on a iron
deficient diet into the lactation period produced milk with
normal carnitine concentrations but reduced iron
concentrations (85). On day 2 after birth there was no
difference in carnitine concentrations in the pups, but on
day 16 liver carnitine was about half that of iron
sufficient pups. Rat pups are not fully able to synthesize
carnitine until 8 days after birth (86), so the effect of
iron deficiency on their own carnitine synthesis would not
be expected to be seen very soon after birth. This
demonstrates that iron deficiency may result in impaired
carnitine synthesis and may also explain the
hypertriglyceridemia seen in the iron deficient pups.
Carni�ine and fa��y acid me�abolism:
The transport of long chain fatty acids across the
inner mitochondrial membrane into the matrix of the
mitochondria is the best characterized function of carnitine
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(65). This process involves the activation of a fatty acid
by coupling to coenzyme A (CoA) via a thioester bond,
followed by transfer of the acyl group to carnitine,
translocation of the acylcarnitine across the inner
membrane, and transfer of the acyl group to
intramitochondrial CoA (9). The first step in carnitine
mediated transport of fatty acids across the inner
mitochondrial membrane is the cytosolic generation of acyl
CoA which diffuses across the outer membrane into the inter
membrane space.
Carnitine palmitoyltransferase I (CPTl) spans the
outer mitochondrial membrane, with the transferase active
site on the inside of the membrane and a malonyl CoA binding
site on the cytosolic side. The active site transfers the
acyl group of the acyl-CoA to carnitine to make an
acylcarnitine (65).
Binding of malonyl CoA to the cytosolic side of the
CPTl inhibits the enzyme and assures that acyl groups will
not be transported into the mitochondria for oxidation at
the same time that fats are being synthesized (88).
Carnitine-acylcarnitine translocase shuttles the
acylcarnitine across the inner mitochondrial membrane where
another CPT (CPT2 ) transfers the acyl group back to
intramitochondrial CoA after which it proceeds to oxidation
(65).

The reverse of the process for transporting long

chain fatty acids into the mitochondrial matrix appears to
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be used for removing short and medium chain fatty acids from
the inside of the mitochondria (65).
Other possible functions of carnitine:

Carnitine has been shown to be able to inhibit the
clustering of cells including erythrocytes (89) and the
slime mold Dictyostelium discoideum (90). The carnitine
concentrations required for 50% inhibition of aggregation
are substantially higher than physiological concentrations
of carnitine in plasma at 0.5 mM for erythrocytes and 5-10
mM

for Dictyostelium. The normal concentration of carnitine

in plasma is about 0. 05 mM, so the significance of this
finding is questionable.
The concentration of carnitine in the brain is lower
than most tissues, but still significant (9). The function
of carnitine in the brain is unknown since it does not
utilize fatty acids for energy. Recent studies have
investigated the use of acetyl carnitine for treatment of
neurological disorders. In streptozotocin induced diabetic
rats, treatment with acetylcarnitine was able to reverse
neurological damage as determined by measurement of nerve
conductance velocity (91). In aged rats acetylcarnitine was
able to restore neuromuscular conduction velocity to that of
young rats after 6 months of treatment (92). Human tests
with Alzheimer's disease patients have shown some evidence
that acetylcarnitine may ameliorate the symptoms of the
disease when given orally (93). How acetylcarnitine may
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exert the effects reported on neurological function is
unknown.
The organ most sensitive to carnitine deficiency is the
heart, because the heart relies on fatty acids for about 60%
of its energy needs (8). Primary carnitine deficiency is a
rare syndrome that has been described in children (94). In
this disease plasma carnitine concentrations are very low
resulting in congestive cardiomegaly which can be reversed
by oral carnitine administration. Cardiomegaly can also
develop as a result of carnitine being dialyzed out in
hemodialysis patients and carnitine should be supplemented
in such patients (95). The use of carnitine has been
investigated for treatment of ischemic heart disease, but
the results thus far have been contradictory so it is still
under investigation (8).
Carnitine has also been shown to reduce the hepatic
steatosis seen in chronic alcoholic rats (96). Rats fed a
diet with 36% of the calories from alcohol will accumulate
3-4 times the hepatic lipid content of controls within 8
weeks. Rats supplemented with D,L-carnitine (1% by weight in
the diet or 0. 5% L-carnitine) accumulated less than half the
lipids as did the non-supplemented alcoholic rats. The
effect of carnitine on liver lipids was later shown to be
dose dependent with the greatest effect at 0. 8% D,L
carnitine in the diet (97).
Carnitine was also shown to reduce the rate of alcohol
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disappearance from the blood (98). The effect was not seen
with choline supplementation although choline is very
similar in structure to carnitine (98). It was concluded
that the attenuation of ethanol metabolism was specific for
carnitine. The reduced rate of ethanol clearance was shown
to be the result of reduced oxidation even though the
activity of ethanol oxidizing enzymes was unaffected (99).
The hepatic steatosis resulting from aflatoxin B 1
administration has also been shown to be reduced by
carnitine supplementation (100). Carnitine also reduced
formation of aflatoxin adducts with RNA, DNA, and proteins
in the liver.
Carnitine and the immune system:

The effect of carnitine on cells of the immune system
has been investigated with uncertain results. Borum et al.
reported in 1985 that erythrocytes contain 20-30% of the
blood carnitine (101). In 1987,however, Katrib et al.
reported that erythrocytes had virtually no carnitine and
that high concentrations were found in polymorphonuclear
leukocytes (neutrophils) and mononuclear cells (macrophages
and monocytes) (102).

After that, Furst and Gloggler

reported that erythrocytes had substantial carnitine
concentrations and polymorphonuclear cell and mononuclear
cells had virtually non-detectable concentrations of
carnitine (103). It is difficult to explain why the
different laboratories found such extreme differences in
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carnitine concentrations in blood cells. The group that
found high concentrations of carnitine in immune cells
demonstrated the next year that patients with inflammatory
disorders have decreased concentrations of carnitine in
plasma but increased concentrations in neutrophils (104).
Polymorphonuclear cells were found to have increased acyl
and total carnitine, mononuclear cells to have increased
ratio of acyl to free carnitine but the same total
carnitine, and plasma to have severely decreased free
carnitine but increased acylcarnitines. It is possible that
the activation state of immune cells can have a significant
effect on carnitine concentrations which resulted in the
discrepancies reported between laboratories.
Carnitine excretion:

At normal plasma concentrations about 90% of the
carnitine filtered in the kidney is reabsorbed (105). The
macronutrient content of human diets is known to affect
urinary excretion of carnitine and plasma carnitine
concentrations. High fat diets have been shown to increase
both plasma concentration and carnitine clearance over low
fat diets (106). Plasma carnitine concentrations tend to
remain rather constant at a wide range of dietary intake.
Renal adaptation to carnitine intake appears to be a major
regulator of plasma carnitine concentration (102). Persons
given a diet high in fat, protein, or both excrete
significantly increased amount of carnitine (107). The
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increased carnitine excretion appears to be the result of
increased plasma carnitine resulting an increased filtered
load. Carnitine intakes were constant between groups so the
diet apparently resulted in increased carnitine absorption,
biosynthesis, or release from tissue stores.

Pantothenic Acid
Pantothenic acid is one of the B vitamins and is widely
distributed throughout the food supply. Virtually all foods
contribute significant amount of pantothenic acid to the
diet, however, meats, legumes, and whole grain cereals are
the richest sources (108). Although plentiful, much of the
dietary pantothenic acid may be destroyed in food
preparation, it is reported that cooking meat results in a
15-50% loss of the pantothenic acid (109).
Absorp�ion and �ranspo� of pan�o�henic acid:

Most dietary pantothenic acid is in the form of
coenzyme A, but during digestion it is released from the
coenzyme A molecule and is absorbed as free pantothenate
(110). Approximately 50% of the coenzyme A in the diet is
absorbed (111). The mechanism for intestinal absorption of
pantothenic acid is uncertain, but one recent report has
demonstrated that pantothenate utilizes a sodium cotransport
mechanism in the human placental brush-border membrane
(112). It was also shown that biotin is transported by the
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same mechanism and competes with pantothenic acid. Whether
this mechanism is utilized in the intestinal mucosa is
uncertain.
Func�ions of pan�o�henic acid:

Pantothenic acid has two primary functions, first it is
part of the coenzyme A molecule and second it is the
prosthetic group on acyl carrier protein. As part of the
coenzyme A molecule pantothenic acid is essential to all
energy releasing reactions in the body (113). As part of the
acyl carrier protein, pantothenic acid is essential for the
synthesis of fatty acids (114).
Excre�ion of pan�o�henic acid:

Pantothenic is excreted as the free vitamin in the
urine. Most is derived from the hydrolysis of coenzyme A to
produce pantothene which is further hydrolyzed to
pantothenic acid (114). When excretion of pantothenic acid
drops below 1 mg/d (an amount corresponding to an intake of
< 4 mg/d) a deficiency of the vitamin should be expected
(113).

Interactions Between Nutrients

The concept of a nutrient interacting with another
nutrient in ways that effect the tissue concentrations or
dietary requirement for that nutrient is not new. It was
reported in 1947 that dietary tryptophan reduces the dietary
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requirement for niacin (114,115 ) .
Interaction between vitamin C and iron:

A classical nutrient-nutrient interaction is that between
vitamin c and iron. Vitamin c is able to increase the
absorption of iron by keeping it in the reduced (Fe2+ ) form
and by chelating it and keeping the iron in a more soluble
form (116 ) . Vitamin C is also important in other aspects of
iron metabolism such as synthesis of hemoglobin and the
removal of iron from ferritin (116 ) .
Interaction between calcium and magnesium:

Similar nutrients often affect each other, such is the case
with the two divalent cations calcium and magnesium. It has
been reported that increasing the calcium consumption in
humans can reduce absorption of dietary magnesium (117). In
rats fed a parenteral nutrition diet with graded doses of
calcium, urinary excretion of magnesium increased as calcium
supplementation increased (118 ) . Calcium, therefore , may
decrease absorption and increase excretion of magnesium
simultaneously.
Interaction between choline and carnitine:

Choline and carnitine are also very similar in structure as
shown here.
(CH3 3 -N-CH2-CH-CH2-COOH
)

OH
Carnitine

Choline
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With such striking similarity it would not be surprising if
interactions were found. Rats that are fed a choline
deficient diet have been shown to have reduced carnitine
concentrations in liver, heart, and skeletal muscle, but
increased plasma carnitine concentrations compared to
animals fed a choline supplemented diet (119). Comparisons
were not made to a control diet in this study.
Choline deficiency results in a decrease in lipid
oxidation in heart and liver cells that can be reversed in
vitro by the addition of carnitine (120). The difference in
carnitine levels in this study were even more dramatic after
the animal were fasted for 48 hrs. Carnitine concentrations
increased almost four fold in liver and significantly in
heart and muscle after fasting of the choline supplemented
animals. In the choline deficient animals carnitine
increased in the liver about 3 fold but decreased slightly
in heart and muscle. It would appear that increases in
carnitine concentrations are a part of the adaption to
fasting that is impaired when there is choline deficiency in
rats.
It was shown in another study that the decreased
hepatic carnitine in choline deficient rats results in a
four fold decrease in oxidation of

14

C palmitate and an

increased incorporation into triglyceride in liver
homogenates (120). Addition of carnitine, but not choline ,
in the liver homogenates restored palmitate oxidation to
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control levels and decreased the rate of esterification
palmitate to glycerol. This suggested that the fatty liver
seen in choline deficient rats may be due in part to a lack
of carnitine.
Choline and pantothenic acid supplementation has also
been shown to reduce carnitine concentrations in plasma and
24 hr urine of humans (121,122). Follow-up studies
demonstrated that the effect on carnitine was due to choline
and not pantothenic acid (123). The results of these studies
raised a number of intriguing questions which could not be
adequately answered by reasonable experiments in humans.
The questions included 1) Are the decreases in plasma and
urine carnitine concentrations a reflection of altered
partitioning of carnitine among tisues? 2) Is it mediated
via the carnitine transporters of tissues? 3) What are the
consequences of the decreased carnitine concentrations in
plasma and urine?
Thus a need for an animal model was clearly realized
and the primary objective of this research was to find a
good animal model to study the choline-carnitine
interactions.
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Chapter 3
Materials and Methods

The human research protocol presented here was approved
by the Committee on Research Participation of the University
of Tennessee. The animal research protocols were approved by
the animal care and use committee of the University of
Tennessee. All animals were housed in a AAALAC accredited
animal facility maintained at a constant temperature and
relative humidity of 70° F and 50% respectively.

Experiment in Humans

The human study was conducted on college students age
20-35. Choline only was used in this study because it was
suspected to be causing the effect on carnitine status in
the previous studies. Six female students volunteered to
take the choline supplement (experimental group). The
control group consisted eight female students.
Each subject in the experimental group was provided a
choline supplement (Rexall 300 mg ea. , Ft Lauderdale, Fl. )
and instructed on the number of tablets to take per day to
obtain 0. 165 mol/kg body weight (20 mg/kg). All sub jects
were instructed to eat their normal diets and report any

significant deviations from their normal pattern of eating
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and exercise. After five days of supplementation blood and
urine samples were collected.
Each subject was provided a container containing thymol
crystals and instructed to collect 24 hr urine samples by
voiding and discarding the urine upon rising on the morning
of day 4, and collecting all subsequent urine voids until
the morning of day 5 when the final void was collected at
the exact same time as the discarded first void of the
previous morning. The volume of all urine collections was
measured and a 10 ml aliquot saved and frozen at -20° C until
assayed.
A professional phlebotomist was hired to draw blood
from all subjects. The blood was drawn into vacutainer tubes
containing EDTA (Becton Dickinson, Rutherford, NJ),
centrifuged and the plasma stored at -20° c until assayed.

Experiment Using Rats as an Animal Model
Twelve Sprague-Dawley rats (Harlan Sprague Dawley,
Indianapolis, IN) were purchased and individually housed in
stainless steel wire mesh cages for the duration of the
study except when urine was col lected at which time they
were housed in stainless steel metabolic cages. All animals
were fed Purina Rat Chow #5001 (Ralston Purina Co. , st
Louis, MO) ad libitum for one week prior to the beginning of
the study.
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The twelve animals were randomly divided into four
groups of three and assigned to one of four dietary
supplement treatments. Dietary supplements were either
choline chloride (Mallinckrodt, Paris, KY), or pantothenic
acid (Sigma Chemical Co, st Louis, MO), or both. All groups
were provided food and water ad libitum. Diets were prepared
by grinding rat chow and adding the appropriate supplement.
The groups and supplements received were :
Control
Choline (CH)
Pantothenic Acid (PA)
CH/PA

No
CH
PA
CH

Supplement
21 mmol/kg (2. 5g/kg) diet
0. 5 mmol/kg (100 mg/kg) diet
21 & PA 0. 5 mmol/kg diet.

The choline supplement was approximately 1. 5 times the
amount inherent in the chow and the pantothenic acid about
two fold greater. There were only trace amounts of carnitine
detectable in the chow.
The blood collection procedure was too labor intensive
to allow blood to be drawn from all animals on the same day.
For this reason the groups were paired and staggered with
the control group and the CH/PA groups beginning the diet
and samples collected on the same days. Likewise the CH and
PA groups were paired.
Animals were kept on the experimental diet for 21 days
and blood and urine collected before the study began and at
5 day intervals thereafter. The day of the study was counted
form the day the animals began the experimental diets, which
was a different day for each group.

The schedule was not

strictly adhered to because of problems in obtaining
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samples , but when a day was missed samples were taken again
as soon as possible. Blood was collected by inserting an
intravenous catheter (Insyte intravenous catheter placement
unit , Deseret Medical , Inc , Sandy UT) in a lateral tail
vein. Blood was drawn into a 1. 5 ml microcapillary tube
containing EGTA (Sigma Chemical Co , St Louis , MO ) ,
centrifuged and the plasma frozen at -2 0°c until assayed.
Urine was collected by placing the animals in stainless
steel metabolic cages with the urine draining into 250 ml
Erlenmeyer flasks containing 5 thymol crystals. After 24 hr
the urine was measured, centrifuged and a 10 ml aliquot
frozen at -20° C for future assays.
At the end of the experimental period the animals were
anesthetized with open drop methoxyflurane and sacrificed by
decapitation. Blood was collected by draining from the neck
into a 10 ml tube containing EGTA. Blood was centrifuged and
the plasma frozen at -2 0°c until assayed.

Experiments Using Guinea Pigs as an Animal Model
There were three studies using guinea pigs with the only
difference being the blood and urine collection times and
methods. In each trial 12 guinea pigs were purchased from
SASCO , Inc; Omaha , NE. All animals were individually housed
in stainless steel wire mesh cages except when urine was
being collected. All animals were provided water and Purina
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Purina Guinea Pig Chow #5025 ad libitum for one week prior
to the beginning of the study.
In each study twelve animals were divided into four
groups of three and assigned to one of the four dietary
supplement treatments . All groups were provided food and
water ad libitum. Experimental diets were prepared by
grinding guinea pig chow and adding the appropriate
supplement ( s) . The groups and supplements received were :
Control
Choline ( CH)
Pantothenic Acid ( PA)
CH/PA

No Supplement
25 mmol/kg ( 3mg/kg) diet
0 . 7 mmol/kg ( 150mg/kg) diet
CH 25 & PA 0 . 7 mmol/kg diet

The choline supplement was 1 . 75 times the amount
contained in the diet and the pantothenic acid about two
times the amount i n the diet . There was no detectable amount
of carnitine in the guinea pig chow .
In the first guinea pig trial the experimental diets
were begun one week after arrival . Blood was collected at
the end of the study in the same manner as with the rats .
Urine was collected before the experiment began, and on days
6 and 1 1 of the experimental diets and processed in the same
manner as with the rat uri ne samples . The day 11 urines
contained no carnitine after being stored in the
refrigerator over night prior to processing . In the next
trials urine was immediately centrifuged and frozen and 1 ml
0 . 1 N HCl was used as a preservative .
In the second trial the experimental diets were begun
after one week . Urine was collected before the exper imental
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diet began and on days 6 and 11, and processed the same as
previously except as noted above. Blood samples were
collected at the end of the study in the same manner as with
the rats.
The third guinea pig trial was conducted exactly as the
first except that urine was collected on days

o , 3, 6, and

11. Blood was collected by cardiac puncture on days 3, 6,
and 1 1 , centrifuged and the plasma frozen at - 2 0 ° c until
assayed.
Urine was collected for 2 4 hr in acrylic metabolic
cages with thymol crystals added to the urine collection
bottle in the first trial, and 1 ml of 0 . 1 M HCl added in
the second and third trials. All urine volumes were
recorded, centrifuged and a 1 0 ml aliquot frozen at - 2 0 °c .
Assays

Carnit;ine :

Carnitine was assayed in all blood and urine samples by
a modified radioisotopic method of Cederblad and Linstedt
( 1 2 4 , 1 2 5 ) . In this assay, acid insoluble long-chain acyl

carnitines ( AIAC ) are precipitated using perchloric acid,
leaving the short-chain acid soluble acyl carnitines (ASAC)
and the non-esterified carnitines (NEC) in the supernatant.
An aliquot of the supernatant is assayed to determine the
NEC concentration and another hydrolyzed with 0 . 5 N KOH to
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assay all acid soluble carnitines. ASAC is the difference
between the total acid soluble carnitines and the NEC. The
pellets are drained, washed, suspended in 0. 5 N KOH, and
hydrolyzed in a hot water bath at 60°C for 60 minutes and
assayed for carnitine.
In each case carnitine is assayed by using carnitine
acetyl transferase (Sigma Chemical Co. , St Louis, MO) to
esterify carnitine to a

14

C-acetate from l, C-acetyl CoA
14

(Moravek Biochemicals, Brea, CA). Radioactivity of samples
and standards was determined by a Beckman LS3801 liquid
scintillation counter.
Creat;inine:

Creatinine assays in urine were performed by the Jaffe
reaction according to the method of Taussky and Henry
(126,127). Plasma creatinine was determined using another
modification of the Jaffe reaction by Raffael (128).
Creatinine clearance was calculated using the equation :
Clearance = (U/P)V where U = urine creatinine concentration,
P = plasma creatinine concentration, and V = urine flow in
ml per minute.
ALT and AST:

In the human study, plasma alanine amino-transferase
(ALT) and aspartate amino-transferase (AST) were determined
using Sigma kits 59-UV and 58-UV respectively (Sigma
Chemical Co, St Louis, MO).
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Statistical Analysis

The human study had only two groups and they were
tested for significance using the Student's t test (P <
0. 05). The rat study had four groups but only two groups
were compared directly, therefore the t test was used to
test significance in this experiment also (P < 0. 05).
In the guinea pig studies there were four groups.
Differences in the means were determined by analysis of
variance (ANOVA) and the Fisher's least significant
difference test. Guinea pig data was also expressed as two
groups (choline supplemented or not supplemented) and the
means compared using a two tailed Student's t test
(p � •05).
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Chapter 4
Results
Experiment in Humans
No subjects reported any adverse effects associated
with choline supplementation and none reported any illness
during the study.

Serum ALT and AST remained within the

normal range for all sub jects which indicated no liver
damage due to choline treatment. In choline deficiency these
enzymes have been shown to be elevated (64).
Urinary and plasma carnitine and urinary creatinine
concentrations are summarized in table 3. Urinary excretion
of creatinine was significantly lower in choline
supplemented sub jects compared to controls (figure 1).
Plasma carnitine concentrations were lower in the choline
supplemented sub jects than in controls, but the difference
was not statistically significant (figure 2). Urinary
excretion of carnitine in the choline group was one third of
the excretion in the control group and the difference was
statistically significant (figure 3). When expressed as µmol
carnitine/gram creatinine per day, the choline group still
excreted less than half the carnitine of the control group.
Carnitine clearance was also significantly lower in the
choline group than the control group (figure 4).
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Table 3
Effect of Choline Supplementation on Carnitine
and Creatinine in Humans
Parameter
Plasma Carnitine (µmol /L)
24 Hour Urine
Carnitine (µmol /day)
Renal Clearance
of Carnitine (ml /minute )
24 Hour Urine
creatinine (grams/day)

Control Group

Choline Group

± 3.1

23 . 7

± 3.1

1 74 . 6

±

3 5 • 8a

55 . 6

± 8 . gb

4.5

±

Q•g

1.8

± 0 . 4b

27 . 7

a

2 . 23 + 0 . J o a

1 . 60 ± 0 . 12 b

Values are the group mean ± SEM . D i f f erent subscri pts
indicate statistical significance at P < 0 . 0 5 by student ' s t
test (control n = 8 , chol ine n = 6 ) .
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Figure 1 : Effect of chol ine supplementation on
creatinine excretion in humans .

Creatin i ne was determi ned i n samples from 24 hr urine
collections. Values represent the group mean ± SEM. The
means di f fered statistical ly at P < 0. 05 by student ' s t
test ( control n = 8, chol ine n = 6).
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Figure 2 : Effect of chol ine supplementation on pl asma
carnitine in hum.ans .

Values represent the means for the groups ± SEM. The
group means did not differ significantly at
P < 0. 0 5 by Student ' s t test ( control n = 8, cho line
n = 6).
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Figure 3 : Effect of chol ine supplementation on urinary
excretion of carnitine in humans .
Va lues represent the group means ± SEM . The va lue s
d i f fered stat i st i ca l l y at P < 0 . 0 1 by student ' s t te st
( control n = 8 , cho l i ne n = 6 ) .
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Figure 4 : Effect of choline supplementation on renal
clearance of plasma carnitine in humans .

Values represent the means for the groups ± SEM. For
the choline supplemented group n=6, and the control
group n=B. Values differed statistically at P = 0. 01
using student ' s T test.
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Experiment Usin& Rats as an Animal Model

No overt toxic effects due to choline or pantothenic
acid supplementation was observed during the study. All
animals ate normally and gained normal weight during the
experimental period (47 grams average weight gain).
Plasma concentration of carnitine did not differ
significantly for either pair at any day during the
experiment (table 4 & figure 5). Urinary excretion of
carnitine was significantly lower in the choline
supplemented group than for the pantothenic acid group on
day 21. There were no other days with statistically
different excretions of carnitine for either group (table 5
& figure 6).
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Table 4
Comparison of Group Means of Plasma Total
Camitine in Rats
Group

Total Carnitine µmol/L

Day of Study

Control
Choline
PA
Choline/PA

0
0
0
0

34. 47
31. 9 7
35. 43
34. 13

Choline
PA

3
3

39. 60
50. 17

Control
Choline/PA

6
6

33. 83
34. 53

Choline
PA

7
7

41. 40
50. 33

Control
Choline/PA

9
9

44. 4 0
39. 4 0

Choline
PA

10
10

44. 93
51. 6 0

Control
Choline/PA

13
13

49. 4 0
43. 40

Choline
PA

14
14

46. 0 0
58 .. 33

Control
Choli ne/PA

16
16

47. 10
44. 8 0

Choline
PA

17
17

53. 43
60. 40

Control
Choline/PA

20
20

65. 83
60. 9 0

Choline
PA

21
21

53. 53
52. 15

Choline
PA

22
22

60. 47
64. 33

Choline/PA = Choline plus pantothenic acid supplemented
group. PA = Pantothenic acid supplemented group
None of the compared means differ significantly by students
t-test at p � 0 . 05 .
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Figure 5 : Effect of choline , pantothenic acid ( PA ) , or both on plasma
carnitine in rats . Each value represents the group mean for that time
point . For each group n=3 . There were no s ignificant differences between
paired groups at any time point at P < 0 . 0 5 us ing Student ' s t test .

Table 5
Comparison of Group Means of Urinary Excretion of
Total Camitine in Rats
Group

Day of Study

Total Carnitine nmol/d

Choline

0
0

635
777

PA

Choline

3
3

564
682

Control
Choline/PA

6
6

491
437

Choline

PA

7
7

520
835

Control
Choline/PA

8
8

692
735

Choline

PA

10
10

492
852

Control
Choline/PA

12
12

582
689

PA

Choline

13
13

655
1069

Control
Choline/PA

15
15

804
813

PA

Choline

17
17

885
869

Control
Choline/PA

19
19

1080
583

Choline

21
21

7 5 64

PA

PA

1430b

Choline/PA = Choline plus pantothenic acid supplemented
group. PA = Pantothenic acid supplemented group.
Different superscript letters beside values indicates
significant difference between the group means at P � 0. 05
by Student's t test.
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Figure 6 : Effect of choline , pantothenic acid ( PA ) , or both on urinary
excretion of carnitine in rats . Each value represents the group means
for that time point . For each group n=3 . Only the day 21 difference was
statistically significant at P < 0 . 0 5 using Student ' s t test .

Experi ments Using Guinea Pigs as an Experimenta l Model

First guinea pig study :

There were no apparent adverse effects of choline or
pantothenic acid supplementation . All animals gained weight,
average of 45 grams, and ate normally throughout the study
period . Urine was collected on the day prior to beginning
the experimental diet, and on days 5 and

1 0 of the of the

experimental diet . Because the urine from the f inal
collection was lost, only the pre diet and f irst post diet
urinary excretions were able to be presented . Plasma was
collected on day 1 0 when the animals were sacri ficed . Plasma
concentrations and urinary excretion of carnitine are shown
in table 6 with all values expressed as means for the group
± the standard error of the mean (SEM) . Urinary excretion of
carnitine is depicted for all groups in f i gure 7 . Figure 8
shows the results when both choline supplemented groups are
combined and both groups not supplemented with choline are
combined .
Plasma total carnitines were higher in all experimental
groups than in the control group . The choline and
pantothenic acid groups were not signif icantly di f ferent
from each other but the choline/pantothenic acid group was
significantly higher than all other groups . The higher value
was due primarily to one animal with an exceptionally high
acid soluble acyl carnitine (ASAC) concentration .
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Table 6
Comparison of Group M eans of Urinary Excretion and Plasma
Concentration of Carnitine in Guinea Pigs ( First Study)
Group

Carnitine µmol/L ( pl asma ) or µmol /d ( 2 4 h ur ine )
NEC

ASAC

Total

AIAC

Pre Experimental Di et Carnitine Excretion
Control
Choline
PA
CH/PA

0 . 88
2 . 04
2 . 11
1 . 43

±
±
±
±

0 . 07
0 . 15
0 . 21
0 . 02

0 . 85
1 . 50
1 . 91
1 . 00

±
±
±
±

0 . 31
0 . 26
0 . 47
0 . 26

0 . 00
0 . 09
0 . 03
0 . 02

±
±
±
±

0 . 00
0 . 09
0 . 00
0 . 00

1 . 74
3 . 63
4 . 05
2 . 45

±
±
±
±

0 . 39
0 . 21
0 . 32
0 . 30

±
±
±
±

0 . 88
0 . 02
0 . 68
0 . 20

Post Experimental Diet Carnitine Excretion
Control
Chol ine
PA
CH/PA

1 . 59
0 . 20
1 . 78
0 . 48

±
±
±
±

0 . 70
0 . 08
0 . 05
0 . 13

0 . 56
0 . 25
1 . 14
0 . 29

±
±
±
±

0 . 01
0 . 04
0 . 32
0 . 04

0 . 00
0 . 02
0 . 00
0 . 00

±
±
±
±

0 . 00
0 . 00
0 . 00
0 . 00

2 . 71
0 . 69
4 . 05
1 . 07

Post Experimental Di et Pl asma Carnitine
Control
Chol ine
PA
CH/PA

37 . 93 ± 2 . 3 4 . 57 ± 0 . 3
4 5 . 1 3 ± 2 . 0 9 . 57 ± 1 . 7
38 . 80 ± 4 . 1 4 . 10 ± 0 . 5
47 . 3 2 ± 3 . 4 16 . 90 ± 8 . 1

0 . 80 ±
0 . 70 ±
0 . 80 ±
0 . 80 +

0.1
0.1
0.1
0.0

43 . 30
55 . 40
4 3 . 70
63 . 93

±
±
±
±

2.2
1.5
4.0
6.2

PA = Pantothenic aci d supplemented group .
CH/PA = Chol ine + Pantothenic acid suppl emented group .
NEC = non-esterif ied carnitine ( free carnitine ) , ASAC = acid
soluble acyl carnitine ( short cha in acyl carnitne ) , AIAC =
acid insoluble acyl carnitine ( long chain acyl carnitine ) ,
Total = total carnitine ( NEC + ASAC + AIAC ) .
Value s are the means for the group ± SEM ( n = 3 ) .
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Figure 8 : Effect of choline on urinary excretion of
carnitine in guinea pigs . The pantothenic acid group was
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No significant differences between groups were found in
any of the carnitine fractions in the 24 hr urine
collections prior to the experimental diets. When the
results were expressed as two groups (choline and no
choline), there was very little difference between groups in
the first collection and again was not statistically
significant.
In the second urine collection (day 5 of the
experimental diet period) there was a clear trend. Urinary
excretion of carnitine was lower in both of the choline
supplemented groups compared to the control group, the
latter being similar to the pantothenic acid supplemented
group. Carnitine excretion was increased in the control
group and remained the same in the pantothenic acid
supplemented group. In spite of the differences, values were
not statistically significant among the four groups by
Fisher's least significant difference test. When the animals
were divided into choline supplemented and non supplemented
groups, the choline supplemented group had significantly
lower urinary excretion of carnitine (p � 0. 01) by Student's
t test.
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Second Guinea Pig Study :

Throughout the study animals no animals exhibited signs
of adverse effects from the supplements; all ate normally,
and gained weight with one exception. Animal #35 in the
pantothenic acid supplemented group lost weight and ate very
little during the last week of the study, indicating that
the animal was sick. As a result, the final urine collection
and the plasma collection data were eliminated.
Plasma was collected at the end of the study when the
animals were sacrificed. Urine was collected on days o ( pre
diet) and on days 6 and 11 of the experimental diet period.
Urinary excretion and plasma concentrations of carnitine are
expressed in table 7 as the means for the groups. Mean
urinary excretion of carnitine is shown for all groups in
figure 9, and figure 10 shows the two choline supplemented
groups combined and the two groups not supplemented with
choline combined.
The choline supplemented group had significantly higher
plasma NEC, ASAC, and total carnitine than did the control
group. The pantothenic acid supplemented group also had
significantly higher ASAC than did the control group.
Urinary excretion of carnitine did not differ significantly
among the groups prior to the experimental diets when
expressed either as individual groups or as pooled groups of
choline supplemented or non-supplemented. The urinary
excretions of NEC and total carnitine were significantly
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Table 7
Comparison of Group Means of Urinary Excretion and Plasma
Concentration of Carnitine in Guinea Pigs (Second Study)
Group

Carnitine µmol/L ( plasma) or µmol/d ( 24 h urine)
NEC

Control
Choline
PA
CH/PA

Day 11
35. 5a
52. 0 b
37. 54
42. 0 ab

ASAC
of Experimental
± 2. 2 12. 4 ab ±
± 3. 1 4 8 • 3b +
± 1. 0 41. 9ab
± 2 • 1 36 • 1
±

±

Total

AIAC

Diet , Plasma Carnitine
5. 0 2. 0 a ± 0. 4 49. 8 4 ± 7. 2
5. 5 1. 5ab ± 0. 3 101. 7 bc ± 7. 9
8. 8 0. 6 b ± 0 . 2 7 9. B ab ± 9. 5
3 • 8 0 • 7 ab ± 0 • 3 7 8 • 7 ac ± 5. 3

Day O ( Pre-Experimental Diet) , Carnitine Excretion
Control 0. 9
Choline 1. 1
PA
1. 3
CH/PA
1. 2

±
±
±
±

0. 2

0. 2
0. 1
0. 3

0. 3
0. 2
0. 5
0. 6

±
±
±
±

0. 1
0. 0
0. 1
0. 3

0. 1
0. 2
0. 1
0. 1

±
±
±
±

0. 0
0 .1

a.a

0. 1

1. 3
1. 5
1. 8
1. 9

±
+
±
±

0. 1
0. 3
0. 2
0. 6

+
±
±
±

0. 2
0. 2
0. 4
0. 3

Day 6 of Experimental Diet , Carnitine Excretion
Control 1 . 58
Choline 0. 3b
PA
1. l ab
CH/PA
0. 5b

+
±
±
+

0. 2
0. 1
0. 4
0. 2

0. 5
0. 1
0. 4
0. 4

+
±
±
±

0. 2
0. 0
0. 1
0. 1

0. 1

a.a

0. 0
0. 1

±
±
±
±

0. 0

a.a

0. 0
0.0

2. o a
0. 5b
1. 5ab
0. g ab

Day 11 of Experimental Diet , Carnitine Excretion
Control
Choline
PA
CH/PA

1. 7 a
0. 6 b
1. 2ab
0. 5b

+ 0. 3
+ 0. 2
+ 0. 4
± a.a

1. 0
0. 5
0. 5
0. 6

±
±
±
±

0. 4
0. 2
0. 2
0. 0

a.a

0. 0
0. 0
0. 1

±
±
±
±

0. 0
0. 0
0. 0
0. 1

2. 7
1. l b
1. 7ab
1. l b

±
±
±
±

0. 6
0. 5
0. 5
0. 1

PA = Pantothenic acid supplemented group.
CH/PA = Choline + pantothenic acid supplemented group. NEC =
non-esterified carnitine ( free carnitine) , ASAC = acid
soluble acyl carnitine ( short chain acyl carnitines) , AIAC =
acid insoluble acyl carnitines ( long chain acyl carnitines) ,
and Total = total carnitines ( NEC + ASAC + AIAC).
Values are the means for the group ± SEM ( n = 3).
Different superscripts indicate statitically significant
differences by Fisher ' s least significant difference test
( P < 0. 5).
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Figure 9 : Effect of choline , pantothenic acid ( PA ) , or both
( CH/PA ) on urinary excretion of carnitine in guinea pigs
( Second study ) . Each value represents the group means ± SEM .
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Figure 1 0 : Effect of choline on urinary excretion of
carnitine in guinea pigs ( Second Study ) . The pantothenic
acid supplemented group in this study was combined with the
control group and both choline supplemented groups were
combined . For each of the combined groups n = 6 except at
day 1 1 when n = 5 for the control group . Va lues are the
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lower for the choline supplemented group than control on day
6. When expressed as choline supplemented or non
supplemented pooled groups there was no significant
difference between groups on day 6. Day 11 NEC and total
carnitines , however , were significantly lower for the
choline supplemented group and the CH/PA groups than for the
control group , but not the pantothenic acid group. When
expressed as pooled choline supplemented or non-supplemented
groups , total carnitine excretion was significantly lower (P
< 0. 01) by Student's t test on day 11.
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Third guinea pig study :

There were no apparent adverse effects dietary
treatments during this study. All animals ate normally and
gained weight ( average 68 grams). Blood was collected on
days 3 and 5 in addition to the end of the study. Plasma
carnitine concentrations are shown in table 8 and urinary
excretion of carnitine in table 9. Figure 11 shows the
urinary excretion of carnitine by groups and figure 12 shows
the pooled groups with both choline supplemented groups and
both non-supplemented groups combined.
Plasma carnitine concentrations did not differ between
groups significantly during the study. Urinary carnitine
excretion was consistently lower for the choline
supplemented animals than non supplemented. When the data
was divided into the four groups, the differences were
statistically significant only on day 11, the final
collection. The choline group had significantly lower NEC
and total carnitine excretion than the control group but was
not significantly different from the groups supplemented
with pantothenic acid or pantothenic acid and choline.
When carnitine excretion data was divided into choline
supplemented or not supplemented, there was no significant
differences on days O and day 11, although day 11 was almost
significant ( P � 0. 07). Excretion of total carnitine was
significantly lower on days 3 and 6 for choline supplemented
animals ( figure 12).
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Table 8
Effect of Supplementation With Choline, Pa ntot henic Acid or
Both on Plasma Concentrations of Carnitine i n Guinea Pigs
(Third Study)
Group

Carnitine µmol/L
NEC

ASAC

Total

AIAC

Day 3 of Experimental Diet
Control
Choline
PA
CH/PA

16. 1
18. 2
19. 5
21. 1

± 2.1
± 0. 9
± 2. 0
± 0 .4

2. 9
o. 8
4. 9
8.5

±
±
±
±

0 .1

a.a

0. 9
1. 6

1. 3
0. 4
0. 8
0. 8

± 0. 4
± 0. 2
+ 0. 1
± 0. 4

20 . 3
19. 4
25 . 2
29. 6

±
±
±
±

3 .6
0. 4
1. 3
3. 0

26. 7
23. 7
23. 0
27. 2

±
±
±
±

0. 2
1. 7
1. 0
0.9

2 3. 5
25. 1
28. 7
28. 0

± 1. 3
± 1. 8
± 2. 3

Day 6 of Experimental Diet
Control
Choline
PA
CH/PA

17. 8
18. 6
19. 1
20 . 7

± 1. 5
± 0.9
± 1. 6
± 0. 3

8. 5 ± 1. 6
4. 8 ± 0. 2
3 . 3 ± 0. 5
5. 7 ± 0. 9

0. 5
0. 4
0. 5
0.8

±
±
±
±

0. 2
0. 5
0. 3
0. 1

Day 11 of Experimental Diet
Control
Choline
PA
CH/PA

18. 6
20. 7
22. 0
22. 4

± 0. 7
± 2. 2
± 7. 5
± 2. 5

4. 2 ± 0. 8
3 . 8 ± 0. 7
6 . 0 ± 2. 4
4. 8 ± 1. 2

0. 6 ± 0. 2

± 0.1
0 . 7 ± 0. 1
0. 8 ± 0 . 2
0.6

+ 3 .5

PA = patntothenic acid supplemented group. CH/PA = choline
and pantothenic acid supplemented group. NEC = non
esterif ied carnitine ( free carnitine) , ASAC = acid soluble
acyl carnitine ( short chain acyl carnitines) , AIAC = acid
insoluble acyl carnitine ( long chain acyl carnitine) , and
Total = total carnitine ( NEC + ASAC + AIAC). Values are means
for the group ± SEM. Means for the groups did not vary
significantly at any time point.
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Table 9
Effect of Supplementation with Choline, Pantothenic Acid or Both on
Urinary Excretion of Camitine in Guinea Pigs (Third study)
Group

Carnitine µmol/Day
NEC

ASAC

AIAC

Total

Day 0 of Experimental Diet, Pre Experimental Diet
Control 0. 8
Choline 0. 6
PA
0.8
CH/PA
0. 8
Control 0. 7
Choline 0. 2
PA
0. 9
CH/PA
0. 3

±
±
±
±

±
±
±
±

0. 2
0. 1
0. 2
0. 1

0.4

0. 3
0. 3
0. 5

+ 0. 1

± 0. 1
± 0. 1
± 0. 1

0. 1
0. 3
0. 1
0. 1

1. 3
0. 9
1. 2
1. 4

±
±
±
±

0. 2
0. 2
0. 2
0. 3

1. 1
0. 9
1. 3
1. 0

±
±
±
±

0. 4
0. 0
0. 2
0. 1

1. 0
0. 9
1. 7
0. 9

± 0. 1
± 0. 0

Day 3 of Experimental Diet
0. 3
0. 1
0. 2
0. 0

0. 4
0. 6
0. 5
0. 7

±
±
±
±

0. 1
0. 1
0. 1
0. 1

0. 1
0. 1
0. 1
0. 1

Day 6 of Experimental Diet

Control 0. 5
Choline 0. 4
PA
1. 7
CH/PA
0. 4

± 0. 1
± 0. 1

± 0. 2

± 0. 0

0. 5 ± 0. 1
0. 5 ± 0. 0
1. 0 ± 0. 1
0. 5 ± 0. 0

ND
ND
ND
ND

± 0. 2
± 0. 0

Day 11 of Experimental Diet
Control 1 . 6 8
Choline 0. 7b
PA
1. o ab
CH/PA
0 • 68

± 0. 5

± 0. 1
± 0. 1
± 0. 2

0. 9
0. 6
0. 7
1. 0

± 0. 2

± 0. 1
± 0. 1
± 0. 4

ND

ND
ND
ND

± 0. 6
0. g b ± 0. 1
1. 7ab ± 0. 3
1. 7ab ± 0. 6
2 . 5a

PA = pantothenic acid supplemented group. CH/PA = choline
and pantothenic acid group. NEC = non-esterified carnitine
(free carnitine), ASAC = acid soluble acyl carnitine (short
chain acyl carnitine), AIAC = acid insoluble acyl carnitine
(long chain acyl carnitine), Total = total carnitine (NEC +
ASAC + AIAC), ND = non detectable. Values are means for the
group ± SEM (n = 3). Different superscripts indicate
statistical significance by Fisher's least significant
difference test (P � 0. 05).
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Figure 11 : Effect of choline , pantothenic acid ( PA ) , or both
( CH/PA ) on urinary excretion of carnitine in guinea pigs
( third study ) . Each value represents the group means ( n =
3) . Different superscripts indicate statistical significance
by Fisher ' s least significant difference test ( P � 0 . 05).
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( P ,:5. 0 . 05 ) .
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Combined Urinary Excretion Data From Guinea Pig :

Figure 13 shows the results when the urinary excretion
data are pooled from all three guinea pig trials and
expressed as choline supplemented or control. Days 5 or 6
are combined from the trials as are days 10 or 11 and
expressed as 5 and 10 respectively. This way of calculating
data results in 18 animal per group on days o and 5. Because
there was no data on day 10 of the first trial and one
sample is missing from day 11 of the third trial , there are
11 animals per group on day 10.
There were no significant dif ferences in carnitine
excretion on day o of the study (pre-experimental diet). On
days 5 and 10 , however , carnitine excretion was much less
for the choline supplemented animals and the difference
significant (P < 0. 01).
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Figure 13 : Effect of choline supplementation on urinary
excretion of carnitine in guinea pigs ( pooled data ) . Each
value represents the pooled mean for the group from three
trials . For days O and 5 n = 18 , for day 10 n = 11 . The
difference on day O was not statistically significant . The
dif ferences on days 5 and 10 , as indicated by asterisks , were
statistically significant by Student ' s t test (P < 0 . 01 ) .
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Chapter 5
Discussion
Human study :

The data presented here confirmed the results of our
earlier experiments in humans (122,123 ) . This study
complimented earlier studies by looking at a younger
population and by using a separate group as control (in
previous studies each subject served as their own control by
using pre-supplement values for control ) . As in the other
studies, choline supplementation resulted in a
statistically significant decrease in urinary excretion of
carnitine. Plasma carnitine was also significantly decreased
in the choline supplemented subjects in previous studies,
but the decrease was not statistically significant in this
study, possibly due to fewer subjects.
The decreased urinary excretion of creatinine was
unexpected since it was not seen in our previous studies. We
do not believe that the effect on creatinine excretion
reflects impaired renal function that could explain
decreased carnitine because it was much less than the
decrease in carnitine excretion (28% and 68% respectively ) .
ALT and AST remained in the normal range for both
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groups during the study (ALT 20. 5 units/ml for choline group
and 15. 5 for controls; AST 25. 5 units/ml for choline group
and 16. 6 for controls), indicating a lack of hepatotoxic
effects for choline in the doses used in this study. Choline
deficiency has been reported to cause liver abnormalities as
evidenced by increased plasma ALT and AST activity (2). This
has not been reported in choline supplementation, but
neither could the possibility be ruled out prior to this
study.
This study left many questions unanswered that can not
be adequately addressed in experiments on humans subjects.
For example, what are the physiological implications of the
reduced plasma and/or urinary excretion of carnitine. Are
the changes in carnitine homeostasis seen in these studies
reflected in tissue concentrations of carnitine? What is
responsible for the changes seen? Since urinary excretion of
carnitine is reduced, and plasma concentrations of carnitine
are either decreased or remain the same, either absorption
of dietary carnitine is impaired, carnitine biosynthesis
decreased, or carnitine is shifted to a different body pool
and carnitine conserved as evidenced by the decreased
urinary excretion.
Since many of these issues can not be adequately
addressed in humans, an animal model was needed to
investigate the mechanisms and consequences of the effects
of choline and/or pantothenic acid on carnitine homeostasis.
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Development of an Animal Model
Rats as an animal model :

The laboratory rat was a natural choice as an animal
model because it is the most commonly used animal in studies
of carnitine, choline and pantothenic acid. It also has the
advantage of being relatively inexpensive, easy to draw
blood from, routinely maintained in our facility, and the
animals that were previously used to study the effects of
choline and carnitine on alcohol metabolism in this
laboratory (81, 96, 97, 98, 98, 99).
While our study was in progress another investigator
reported supplementing rats with only choline for 21 days
after which no differences were found in plasma or liver
concentrations of carnitine or in urinary excretion of
carnitine (129). That study lasted for a longer time and
samples taken only at the end of the study, therefore, if
the effect of choline on plasma and urine is not permanent,
it may have been missed. This study also did not supplement
with pantothenic acid so its possible involvement was not
determined in rats. We still had not determined if the
effect was due to choline or pantothenic acid.
The results of the study in rats was disappointing. No
significant differences could be seen in urinary excretion
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or plasma carn itine during the course of the study except on
the last day of the study . On that day we observed a
significant difference between the pantothenic acid group
and the choline group . It was diff icult to tell if that was
a real difference, however . Although stati stically
significant , at the previous sampling time ( day 15) both
groups had nearly the exact same carnitine excretion . The
best that could be said is that there was a faint trend
seen, choline supplemented rats usually had slightly lowered
carnitine excretion .
It was obvious that a better animal model was needed to
explain the observed effect of choline and pantothenic acid
supplementation on carnitine status in humans . Previous
studies of choline metaboli sm in rats have usually
investigated the effects of choline deficiency . The high
choline oxidase activity of rat liver probably makes it easy
to induce choline deficiency by feeding choline deficient
diets . Rats fed a choline free diet for only two days will
have liver free carnitine reduced by 50% ( 13 0) . The
decreased liver free choline apparently had functional
consequences as well s ince liver triglyceride was reduced
four fold i n the choli ne deficient animals . We were
attempting to see the effect of choline supplementation
rather than depletion and using similar dosages per kg body
weight to that used in the human studies . It seems likely
that us ing much higher dosages of choline could overcome the
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effect of high choline oxidase activity in rats, but we felt
that an animal model that responds similarly to humans at
the same dosages of choline and pantothenic acid would
provide a more suitable model.
The animal with the nearest reported choline oxidase
activity to humans is the guinea pig. The guinea pig has
choline oxidase activity about 3 times that of humans but
the rat has about 60 times the activity. It was logical,
therefore, that if the choline was responsible for the
effect seen in humans, then guinea pigs should be a
potential model for further investigation.
Experiments using guinea pigs as an animal model :

The first two guinea pig studies had blood taken only
at the end of the study instead of throughout as in the
rats. During the third and final guinea pig study blood was
drawn by cardiac puncture throughout the study.
Three questions were addressed in the three guinea pig
trials. The first trial clearly showed that as in humans,
choline but not pantothenic acid supplementation causes
decreased urinary excretion of carnitine. The second study
provided a time course to look at the effect throughout the
study. The third study addressed the question of plasma
carnitine. The decreased plasma carnitine concentrations
seen in humans were not seen in guinea pigs, and this was
confirmed at three, six, and 11 days of supplementation in
the third study.
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The urinary excretion of carnitine in guinea pigs was
more consistent with the observations in humans. In all
three studies there was reduced excretion of carnitine in
the choline supplemented animals. The differences were
greatest in the first two studies , and statistically
significant. Pantothenic acid did not affect urinary
carnitine , but rather minimized the effect of choline in the
groups supplemented with both choline and pantothenic acid.
The results of the urinary excretion of carnitine in
the third study were not quite as clear as the first two
studies. The same excretion trends were seen but to a much
lesser degree and with statistically significant difference
being obtained only on the last day , at which time the
choline supplemented group had a significantly reduced
urinary excretion of carnitine compared with the control
group but no other groups. When the data was viewed as
choline supplemented and non-supplemented groups, the
differences were greater and statistically significant on
days 3 and 5. The statistics were made more difficult
throughout the study because of rather high variation within
groups and only three animals per group.
The reason for smaller differences in total carnitine
excretion between groups in the third study was due to
higher excretion of ASAC in the choline supplemented
animals. Excretion of NEC was reduced similarly to that seen
in the first two studies but the ASAC excretion
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increased

in the third study , resulting in a much smaller change in
total carnitine as opposed to the first two guinea pig
studies.
Two primary conclusions were drawn from these studies.
First , the guinea pig is a better animal model than the rat
for studying choline/carnitine interactions in humans.
Secondly , choline and not pantothenic acid supplementation
is responsible for the decreased excretion of carnitine seen
in humans and guinea pigs.
Other Observations From The Studies
Effect of age on carnitine excretion :

In all of the animal studies young growing animals were
used. Because of the rapid growth of young rodents it should
be expected that age related changes in biological
parameters , including carnitine, could be seen in a few
weeks time. Rats reach sexual maturity at about 100 days of
age and guinea pigs at 100-150 days (132).
In the rat and guinea pig studies there was a clear
upward trend in urinary excretion of carnitine. The same
upward trend in plasma carnitine concentrations was seen in
rats. Since blood was collected only at the end of the first
two guinea pig studies, it was not possible to look for a
similar trend in those studies. The third guinea pig study
was unlike the first two in this regard. Urinary excretion
74

of carnitine declined for the second and third urine
collections and increased back to a concentration closer to
the pre diet collection at the end of the study. Plasma
concentrations remained rather constant throughout the
study. It should be remembered that the guinea pig study
lasted for about half the time of the rat study so age
changes could be more important in the rats. Future studies
should evaluate the effect of age on carnitine concentration
in laboratory animals.
Urinary Excretion versus plasma concentration of carnitine :

Plasma concentration of carnitine appeared to be a less
sensitive indicator of changes in carnitine status than did
the urinary excretion in all of these studies. Other studies
in humans also demonstrated a greater reduction in urinary
excretion of carnitine than in plasma concentrations of
carnitine (133). This same trend is apparent in data
published by other laboratories as well. Table 10 shows
plasma concentrations and urinary excretion of carnitine in
humans who eat meat containing diets (high carnitine),
lactoovovegetarian diets (medium carnitine), and strict
vegetarian diets (low carnitine) (67).
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Table 1 O
Plasma and Urinary Carnitine in H u man Males With Diets of
Varying Carnitine Content
Carnitine Content
of Diet
High
Medium
Low

Plasma Total
Carnitine

Urinary Excretion
of Carnitine

µmol/L

µmol/kg/d

49 . 4 ± 7. 3
45. 9 ± 8. 2
46. 7 ± 8. 1

5. 79 ± 3. 08
2. 10 ± 0. 76
1. 36 ± 0. 49

Taken from reference 67 by Lombard et al.

In table 10 there was no significant effect of diet on
plasma carnitine but urinary excretion of carnitine in the
subjects with low carnitine diets was 18% that of those with
a high carnitine diet. No data is yet available to correlate
plasma and urinary carnitine data with tissue content of
carnitine. Both our data that of others shown in table 10
strongly suggest that plasma carnitine is an inadequate
index of carnitine status and should be combined with
urinary excretion data.
Changes in fatty acid oxidation :

Carnitine performs an obligatory role in fatty acid
oxidation, therefore it is appropriate to question if
factors affecting carnitine metabolism are also affecting
fatty acid oxidation. The third guinea pig study was
particularly interesting because of the simultaneous
increased acyl carnitines and decreased NEC. It has been
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shown previously that increased acyl carnitines and
increased ratios of acyl to free carnitines are positively
correlated with plasma B-hydroxybutyrate concentrations and
therefore oxidation of fatty acids in rats (134).

Table 11

shows the relationship of acyl carnitines to B
hydroxybutyrate in that study. The acyl carnitine
concentrations were highly correlated to B-hydroxybutyrate
concentrations (r = 0. 99) as were the ratio of acyl to free
carnitine (r = 0. 96).
The increases in acyl carnitines seen in the third
group of guinea pigs deserves further study because it may
indicate that choline caused an increase in fatty acid
oxidation that resulted in an increased need for carnitine.
If this were the case, the decreased excretion of carnitine
may indicate a conservation of carnitine.

Table 1 1
Effect of Diet on B-hydroxybutyrate and Carnitine in Rats
Diet
High Carb.
High LCT
High MCT

B-hydroxybutyrate Free Carnitine
( µM)

( mM )

0. 043 ± 0. 007
0. 838 ± 0. 73
5. 543 ± 1. 13

39. 2 ± 2. 2
20. 0 ± 1. 9
19. 4 ± 1. 1

Acyl Carnitine
( µM)

12. 3 ± 1. 0
14. 3 ± 1. 3
28. 1 ± 1. 6

Taken from Seccombe et al, reference 134.
High Carb. = high carbohydrate diet, High LCT = high long
chain triglyceride diet, High MCT = high medium chain
triglyceride diet.
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